Scientific Activities and Production
Research > Scientific Activities and Production
This section includes a list of the more recent results (in some cases, research is still in progress) of the medical and scientific research conducted by Aviralia thanks to scientific agreements that were signed by the Foundation with public and private bodies both in Italy and abroad, first of all with Università degli Studi di Roma ‘Tor Vergata’ through a specific Agreement.
- Mechanisms and effects that account for the different HIV replication and for the response to integrase inhibitors in monocyte-derived macrophages ("M/M") and CD4+ T lymphocytes. [*]
The project investigates the kinetics of HIV-1 infection in M/M and in CD4+ lymphocytes and integration in two cell systems, through the use of Technology.
[*] Progetto ricerca supportato da accordo di finanziamento con Merck Sharp & Dohme Corp. (U.S.A.). - Characterization of RAMs of Patients Failing to DRV and Impact on the Subsequent Regimen – Multicentre Retrospective Analysis. [*]
[*] Scientific project conducted in collaboration with Janssen-Cilag (Italy). - Research on CBA’s expanded to herpesvirus infections in monocyte/macrophages and the impact of a variety of CBAs and nucleoside analogues (i.e. tenofovir) on the viral entry and replication process. [*]
Multiparties scientific project aimed to discover the efficacy of antiviral Carbohydrate Binding Agents (CBAs) in various cellular models, as well as to the analyses about the structure of ENV proteins of different viruses potential target of CBAs. The research on CBAs has been recently expanded to herpesvirus infections in monocyte/macrophages and the impact of a variety of CBAs and nucleoside analogues (i.e. tenofovir) on the viral entry and replication process.
[*] Programma pluriennale di ricerca basato su accordo di lavoro congiunto e di finanziamento stipulato con la Katholieke Universiteit Leuven – Rega Institute for Medical Research (Belgium). - Characterization of the HCV-NS3 protease variability among different HCV-genotypes in terms of genetic barriers in the generation of resistance mutations to protease inhibitors in advanced clinical development. [*]
The main goal of this project is to analyze the HCV variability among different genotypes and whether HCV-genotypes have different genetic barriers for drug-resistance development to PIs.
[*] Progetto di ricerca supportato da accordo di finanziamento con MSD Italia (Italy).
- Virological Efficacy and Resistance Profile in HIV-1 Infected Patients Starting Etravirine in Clinical Practice. [*]
The aim of this project is to evaluate the rate of virological response to etravirine-containing regimens in an Italian data set of HIV-1 infected patients using data outside clinical trials.
[*] Progetto scientifico svolto per conto di Janssen-Cilag (Italy). - Characterization of HIV infected patients treated with raltegravir: resistance mutations in failing patients and antiviral efficay on the subsequent regimens. [*]
The main goal of this workis to characterize the population of patients treated with raltegravir, with particular attention on those failing to raltegravir containing regimens.
[*] Progetto di studio supportato da accordo di finanziamento con ViiV Healthcare (Italy). - Virologic response data from subjects treated with ETR. [*]
[*] Progetto scientifico svolto per conto di Janssen R&D (Ireland). - Characterization of innovative genetic markers in the HBV and HCV genoma linked to the development of hepatocellular carcinoma (HCC) with a viral etiology. [*]
This research that is currently (November 2013) in the initial stage, is based on the existing lack of a systematic characterization of viral genetic factors (particularly for the difficulty in sequencing the entire viral genoma) capable of transforming the progression of chronic hepatitis into HCC. To fill these gaps, this research project sets out to analyze the connection between the viral quasispecies and the alteration of pathways involved in the onset of HCC. Results obtained potentially represent a new paradigm for facing a systematic analysis of the cause mechanisms and of the profiles linked to HCV- and HBV-related diseases.
[*] Research project winner of one of the prizes of the Fellowship Program 2013 of Gilead Sciences (Italy). - Collaboration as part of the CHAIN European project (Collaborative HIV and Anti-HIV Drug Resistance Network).
This collaboration is aimed at organizing and conducting training courses as part of the Work Package 7 (WP7) of the European CHAIN project. This training activity aims at transferring adequate knowledge in the HIV Drug resistance network in European countries, inclusive of Eastern European countries, and in Africa. It specifically concerns the following topics:
- epidemiology and monitoring drug resistance;
- clinically managing drug resistance;
- diagnostic tools for properly monitoring drug resistant strains.